HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wellness Industry News: GMP Complaint Against Confidence USA, Crown Labs Expands Again, More

Executive Summary

FDA seeks injunction against Confidence USA; Crown Labs expands again; CHPA, PCPC say Environmental Working Group "irresponsibly misrepresents” evidence on sunscreen safety; Kratom Information & Resource Center says 92% of news about kratom published since February was ‘unfair and unbalanced’; more news.

You may also be interested in...



In Order Shutting Down New York Supplement Firm, Federal Judge Also Criticizes FDA’s Calculations

Judge ordering permanent injunction against Confidence USA on a complaint filed in 2019 questioned FDA's calculations for requiring the firm to recall and destroy all products it had distributed since February 2018.

HBW Market News: FTC Targets Bone Health Claims, Puration Offers To Buy Hemp4mula, More

FTC settled with one firm and is pursuing litigation against another after alleging claimed supplements could grow bone and cartilage; CBD beverage firm Puration offers to acquire Hemp4mula; and Huron Capital’s Ronnoco Beverage business acquires Trident Beverage.

Opioid Abuse Treatment Claims Prompt FDA Warnings To Two Kratom Marketers

As in previous warnings to kratom supplement marketers linked to opioid addiction treatment claims, FDA tells Cali Botanicals and Kratom NC that HHS in 2017 found opioid abuse was nationwide public health emergency and FDA is targeting products that without approval claim to diagnose, mitigate, prevent, treat or cure opioid addiction. Contract manufacturer Somlabs' GMP problems also were identified in FDA's latest warning letters.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

RS148849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel